CFO4Life Group LLC Has $394,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

CFO4Life Group LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,265 shares of the biopharmaceutical company’s stock after purchasing an additional 112 shares during the period. CFO4Life Group LLC’s holdings in Gilead Sciences were worth $394,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter valued at $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on GILD shares. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the stock an “overweight” rating in a research report on Tuesday. Oppenheimer lifted their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Stock Down 0.4 %

Shares of NASDAQ GILD opened at $113.99 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market cap of $141.96 billion, a price-to-earnings ratio of 308.08, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The stock has a 50-day moving average price of $100.99 and a two-hundred day moving average price of $92.33.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.77%. Gilead Sciences’s payout ratio is presently 854.05%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 311,285 shares of company stock worth $31,284,910. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.